Management of Leukopenia with Decreased Neutrophil and Lymphocyte Counts

Assessment and Risk Stratification

The severity of neutropenia should be evaluated based on absolute neutrophil count (ANC): mild (1,000-1,500/mm³), moderate (500-1,000/mm³), or severe (<500/mm³), as recommended by the Infectious Diseases Society of America 1
Assessing for signs of active infection is crucial, especially when ANC <1,000/mm³, and requires immediate intervention, according to the American Society of Clinical Oncology and the Infectious Diseases Society of America 1, 2

For patients with ANC <500/mm³ or febrile neutropenia, broad-spectrum antibiotics should be initiated immediately, as recommended by the Infectious Diseases Society of America 1, 3
Consideration of G-CSF (filgrastim) at 5 μg/kg/day subcutaneously until ANC recovers to >500/mm³ is recommended by the American Society of Clinical Oncology 3
Daily monitoring of complete blood counts is necessary during severe neutropenia, according to the American Academy of Pediatrics and the Infectious Diseases Society of America 1, 4

Antimicrobial prophylaxis should be initiated for prolonged neutropenia, including antibacterial, antifungal, antiviral, and pneumocystis prophylaxis, as recommended by the Society for Immunotherapy of Cancer 3
The American Society of Clinical Oncology recommends antimicrobial prophylaxis for patients with prolonged neutropenia, including levofloxacin or ciprofloxacin 500 mg daily until ANC >500/mm³ 3

Maintaining adequate hydration and nutrition is essential, as recommended by the Infectious Diseases Society of America 1
Transfusing blood products as needed, including maintaining hemoglobin ≥7.0 g/dL and platelets >30,000/mm³, is recommended by the Society for Immunotherapy of Cancer 3
Avoiding medications known to cause bone marrow suppression is advised, according to the American Academy of Child and Adolescent Psychiatry 4

For patients with medication-induced leukopenia, discontinuation of the offending agent should be considered, and monitoring protocols should be followed, as recommended by the American Academy of Child and Adolescent Psychiatry 4, 5
For patients with hematologic malignancies, delaying myelosuppressive chemotherapy in patients with mild neutropenia who are not actively infected should be considered, as recommended by the American Society of Hematology and the Leukemia Society 2, 6

Monitoring CBC weekly until stable or improving is recommended for mild neutropenia (ANC 1,000-1,500/mm³) without symptoms, according to the Infectious Diseases Society of America 1
Daily CBC monitoring until improvement is necessary for severe neutropenia (ANC <500/mm³), as recommended by the American Academy of Pediatrics and the Infectious Diseases Society of America 1, 4

Delaying antibiotics in febrile neutropenia can lead to rapid progression of infection, as warned by the Infectious Diseases Society of America 1
Overlooking the need for antimicrobial prophylaxis in prolonged neutropenia increases infection risk, according to the Society for Immunotherapy of Cancer 3
Neglecting to monitor for recovery of counts after initiating treatment can lead to prolonged neutropenia, as cautioned by the American Academy of Child and Adolescent Psychiatry and the Infectious Diseases Society of America 1, 4